Once thought to be purely an endocrine disorder, a more modern understanding of insulin resistance and glycemic regulation has revealed that prediabetes, type 1 and type 2 diabetes are hugely related to cardiometabolic disease and its many comorbidities. As the understanding of how diabetes is related to conditions like obesity and heart failure grows, more therapeutic targets are being identified, showing promise for many new treatments.
CME/CE Activities
News Digest
Comprehensive Overview of GLP-1 RAs in Cardiometabolic Care
The not-so-sudden rise of weight loss ”wonder” drugs for T2D and obesity This World Obesity Day, March 4, 2024, weight loss drugs dominate discussions and
Cardiometabolic Health Congress (CMHC) To Host DIETARY STRATEGIES FOR REVERSING TYPE 2 DIABETES: Advances, Perspectives, and Expert Discussions Live Webinar in Honor of the Late Dr. Sarah Hallberg
“Once I got to meet Sarah, I realized her TED success was no coincidence; she’s simply a force of nature.” – Dr. Andreas Eenfeldt, founder
How to Get Free or Lower Cost Insulin for Your Medicare and Non-Medicare Patients: Shattering Barriers to Insulin Access
Astronomically high insulin costs have led to complications and barriers to access for millions of Americans with diabetes. After years of pressure from the government
The High Cost of Insulin: Bridging Gaps on the Path to Affordable Care
Why are insulin prices so high? Short history from development to today’s price hikes Doctors Frederick Banting and Charles Best successfully isolated the hormone insulin
Kidney Week 2023: Top Ten Takeaways
More than 12,000 attendees flocked to Philadelphia, Pennsylvania, on Nov. 2-5, 2023, to gain perspective on the latest advances in the management of glomerular disease.
Cardiometabolic Health Congress Becomes First Organization to Offer Certification in Cardiometabolic Health
Learners who complete the Foundations of Cardiometabolic Health Certificate Course offered by Cardiometabolic Health Congress are now eligible to sit for a certification exam to
Day 4 Nightly News: 18th Annual CMHC
On Saturday, Oct. 21, 2023, Cardiometabolic Health Congress (CMHC) celebrated the final day of its 18th Annual Conference, Social Determinants and Digital Advances in Cardiorenal
Day 3 Nightly News: 18th Annual CMHC
The third day of Social Determinants and Digital Advances in Cardiorenal Metabolic Health, the 18th Annual Cardiometabolic Health Congress (CMHC), delivered insights on selecting and
Day 2 Nightly News: 18th Annual CMHC
The cardiorenal metabolic education continued on Thursday, Oct. 19, 2023, when the 18th Annual Cardiometabolic Health Congress (CMHC) launched its second day of sessions at
Day 1 Preconference Nightly News: 18th Annual CMHC
On Wednesday, Oct. 18, 2023, Cardiometabolic Health Congress (CMHC) returned to the Boston Park Plaza for the 18th Annual Conference, Social Determinants and Digital Advances
Why Should We Use CGM in Patients With Type 2 Diabetes?
This clinical brief was developed from a session at the 17th Annual Cardiometabolic Health Congress (CMHC) presented by Irl B Hirsch, MD from the University
Should Diabetes Management be More Adipose-Centric?
This complimentary activity was developed by Neha Agarwal, PhD, Senior Clinical Manager for Cardiometabolic Health Congress (CMHC). It is supported by an educational grant from Lilly
FDA Approves First SGLT1/SGLT2 Inhibitor Sotagliflozin
The U.S. Food and Drug Administration (FDA) announced on May 26, 2023, it had approved the once-daily oral tablet sotagliflozin to reduce the risk of
10 Cardiorenal Stories to Watch
The experts behind Cardiometabolic Health Congress have identified 10 stories in cardiorenal medicine to watch in 2023.
Sanofi Joins Lilly and Novo to Cut Insulin Prices
Sanofi was the last of three pharmaceutical goliaths to announce they’d make good on their long-spoken promise to lower the price of their insulin.
Genetics Link Migraine and Blood Sugar
Research published on Feb. 20, 2023, by Rafiqul Islam, PhD, and colleagues from Queensland University of Technology may have uncovered a concrete link between blood
Lilly Cuts Insulin Prices
In an era when health care and pharmaceutical prices continue to trend upwards, Eli Lilly made a historic announcement on Wednesday, March 1, 2023, stating
Tirzepatide For Weight Loss
Eli LIlly’s tirzepatide (Monjaro) could become the most popular weight-loss drug ever if approved, but there are significant concerns about if it will be affordable
Expert Highlights and Perspectives
DUAL GLP-1/GIP AGONISTS: ARE THEY THE NEXT BIG THING IN DIABETES TREATMENT
(Recorded April 2022)
HOW CAN WE CONVERGE THE GLUCOCENTRIC AND CARDIO-RENAL RISK MANAGEMENT IN DIABETES PATIENTS
(Recorded April 2022)
Drug Pipeline
Drug Pipeline Coming Soon
#C1E5E9
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
#C1E5E9
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
#C1E5E9
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.